Smith-Farrell will lead the next phase of growth as Orbis evolves its platform, advances its pipeline, and builds on its collaboration with Novo Nordisk, valued at up to $1.4 billion Co-founder Morten Graugaard becomes Chief Business Officer, leading business development amid strong partnering momentum COPENHAGEN, October 27, 2026--(BUSINESS WIRE)--Orbis Medicines, a leader in the discovery of next-generation macrocycles, oral medicines with biologics-like potency, today announced the appointment of Joanne Smith-Farrell, Ph.D., as Chief Executive Officer. She succeeds co-founder Morten Graugaard, who becomes Chief Business Officer. Dr.
Nous affichons publiquement l'idee principale. Creez un compte gratuit pour lire l'article complet, l'enregistrer, le commenter et le relier au contexte marches et OSINT.